Bank of New York Mellon Corp Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX)

Bank of New York Mellon Corp raised its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 80.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,162 shares of the company’s stock after purchasing an additional 76,612 shares during the quarter. Bank of New York Mellon Corp’s holdings in Nkarta were worth $1,017,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. RA Capital Management L.P. grew its holdings in shares of Nkarta by 38.4% during the 1st quarter. RA Capital Management L.P. now owns 10,805,129 shares of the company’s stock worth $116,803,000 after purchasing an additional 3,000,000 shares during the period. Commodore Capital LP acquired a new position in Nkarta in the fourth quarter valued at about $18,018,000. SR One Capital Management LP lifted its position in Nkarta by 150.0% in the first quarter. SR One Capital Management LP now owns 3,333,333 shares of the company’s stock valued at $36,033,000 after buying an additional 2,000,000 shares during the last quarter. Boxer Capital LLC purchased a new position in Nkarta during the fourth quarter worth about $9,504,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Nkarta during the first quarter valued at about $9,072,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Stock Performance

Shares of NKTX opened at $5.21 on Friday. The company’s 50-day simple moving average is $5.80 and its 200-day simple moving average is $7.16. Nkarta, Inc. has a 1 year low of $1.28 and a 1 year high of $16.24. The stock has a market capitalization of $257.46 million, a PE ratio of -2.22 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last released its earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. On average, sell-side analysts predict that Nkarta, Inc. will post -1.92 earnings per share for the current year.

Insider Transactions at Nkarta

In other news, insider Alicia J. Hager sold 3,396 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $8.00, for a total value of $27,168.00. Following the sale, the insider now directly owns 103,819 shares in the company, valued at $830,552. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 8.70% of the company’s stock.

Analysts Set New Price Targets

NKTX has been the topic of several recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $13.00 price objective on shares of Nkarta in a report on Wednesday, August 14th. Raymond James raised Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright lowered their price target on Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $18.20.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.